Publisher’s Update – April 2026 This article was originally published in 2015 and remains a helpful overview for newly diagnosed PV patients. One important treatment update: since publication, the FDA has approved Besremi (ropeginterferon alfa-2b) for polycythemia vera. Besremi is a next-generation, long-acting interferon administered every two weeks and is the first interferon specifically FDA-approved […]